Jaguar Health (JAGX) Stock: Buy, Sell, or Hold?
JAGX - Jaguar Health, Inc.
$0.31
-0.01 (-1.57%)
▼
5d:
-54.78%
30d:
-58.68%
90d:
-88.85%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When JAGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: JAGX is down 54.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: JAGX is down 54.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: JAGX is currently trading at $0.31, which is considered oversold relative to its 30-day fair value range of $0.59 to $0.99.
Technical Outlook: Technically, JAGX is in a downtrend. Immediate support is located at $0.29, while resistance sits at $0.86.
Market Sentiment: JAGX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $262.50 (+83498.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JAGX is in a downtrend. Immediate support is located at $0.29, while resistance sits at $0.86.
Market Sentiment: JAGX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $262.50 (+83498.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.59 -
$0.99
Company Quality Score
40/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: Trading 83498.8% below Wall St target ($262.50)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.59 -
$0.99
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.29
Resistance Level
$0.86
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.03
Wall Street Target
$262.50
(+83498.8%)
Revenue Growth (YoY)
-58.9%
Profit Margin
-130.8%
Share & Embed Analysis
Last updated: September 13, 2026 5:45 AM ET
Data refreshes hourly during market hours. Next update: 6:45 AM
Data refreshes hourly during market hours. Next update: 6:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
